When symptoms of myopathy or elevation of creatine kinase occur in the setting of a patient taking statins, the majority of patients may safely continue the treatment with statins. The decision on whether the patient can discontinue or continue statins depends on two factors: the severity of the symptoms and the severity of the increase in the creatine kinase level. Statins can be safely continued when the symptoms are tolerable and the creatine kinase is elevated less than 5 times the upper limits of normal. Otherwise, if the creatine kinase level is higher than five times the upper limit of normal or if the symptoms are intolerable regardless of the level of creatine kinse, statins should be stopped for a certain period of time and restarted again with lower doses or with different types of statins. The role of vitamin D and coenzyme Q10 is still controversial in the management of statin<unk>  myopathy as no studies support their use yet.<
Statin induced myopathy medical therapy
Statin induced myopathy laboratory tests
Polymyositis and dermatomyositis medical therapy
Polymyalgia rheumatica medical therapy
Statin induced myopathy risk factors
Myasthenia gravis medical therapy
Statin induced myopathy differential diagnosis
Statin induced myopathy pathophysiology